June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Retinal Thickness, Retinal Point Sensitivity and Inner Segment/Outer Segment Photoreceptor (IS/OS) Status after Treatment with Ranibizumab in Patients with Diabetic Macular Edema
Author Affiliations & Notes
  • Millena Bittencourt
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Daniel Ferraz
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Jithin Yohanan
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Owhofasa Agbedia
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Mohammad Sadiq
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Yasir Sepah
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Mohamed Ibrahim
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Raafay Sophie
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Mostafa Hanout
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Quan Dong Nguyen
    Retina Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Footnotes
    Commercial Relationships Millena Bittencourt, None; Daniel Ferraz, None; Jithin Yohanan, None; Owhofasa Agbedia, None; Mohammad Sadiq, None; Yasir Sepah, None; Mohamed Ibrahim, None; Raafay Sophie, None; Mostafa Hanout, None; Quan Dong Nguyen, Genentech (F), Regeneron (F), Lux Biosciences (F), Abbott (F), GSK (F), Santen (F), Santen (C), Bausch and Lomb (C), Optos (F), Heidelberg Engineering (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3633. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Millena Bittencourt, Daniel Ferraz, Jithin Yohanan, Owhofasa Agbedia, Mohammad Sadiq, Yasir Sepah, Mohamed Ibrahim, Raafay Sophie, Mostafa Hanout, Quan Dong Nguyen; Retinal Thickness, Retinal Point Sensitivity and Inner Segment/Outer Segment Photoreceptor (IS/OS) Status after Treatment with Ranibizumab in Patients with Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3633.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the changes in retinal thickness, retinal sensitivity and inner segment/outer segment photoreceptor (IS/OS) status after treatment with ranibizumab (RBZ) in patients with diabetic macular edema (DME).

 
Methods
 

A retropective study of patients managed at a university-based retina practice was performed. Microperimetry (MP) and optical coherence tomography (OCT) data was acquired simultaneously with OPTOS/OTI automated system (OPTOS, UK) from DME patients before and after treatment with intravitreal RBZ. Demographic data including, age, gender, severity of diabetic retinopathy, number of injections and follow up time after first injection was also collected. A point-by-point analysis of presence or absence of the IS/OS layer and retinal thickness at every sentitivity point was done by a trained observer. Fixation stability and fixation location were also recorded. The number of standard deviation (SD) from the normal range of retinal thickness and sensitivity stratified by age and location was calculated for each point in the polar 3 pattern. Multivariate analysis was done to verify the effect of RBZ on the variables.

 
Results
 

13 patients (15 eyes) were analyzed. The mean age of patients was 65.8 years (SD ±10.1), 10 patients were male (12 eyes), 9 eyes (60%) had moderate NPDR, 4 eyes (26.7%) had PDR, 1 eye (6.7%) had mild NPDR, and 1 eye (6.7%) had severe NPDR. The mean interval between the pre and post treatment was 5.1 months (SD ±2.7) with an average of 4.7 RBZ injections (SD ±2.4). Number of injections and DR scale have not shown statistically significant effect on the variables changes after treatment (p=0.213; p=0.083). The frequencies of fixation location and stability, as well as the changes in retinal thickness, sensitivity and IS/OS status are summarized on table 1.

 
Conclusions
 

In this pilot study, we have demonstrated that the disruption of the IS/OS junction has an impact on retinal sensitivity of - 3.38dB/- 3.33dB before and after treatment. However, treatment does not change the effect of IS/OS junction disruption on the relationship between retinal sensitivity and retinal thickness. The treatment with RBZ improves the fixation location/stability and the retinal thickness of eyes with DME. Further analyses with a larger sample size are necessary to confirm these results.

   
Keywords: 499 diabetic retinopathy • 642 perimetry • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×